Hematology

Patients with multiple myeloma receiving ASCT showed a 10% increase in tumor cell reduction.

Genetic variation can cause severe acute pancreatitis from chemotherapy in patients with acute lymphoblastic leukemia (ALL).

Treatment of elderly patients with multiple myeloma creates unique hurdles for care providers.

Ibrutinib evaluated in the treatment of chronic lymphocytic leukemia, Waldenström macroglobulinaemia, and mantle cell lymphoma.

Imbruvica approved for use in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Imbruvica approved for use in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Levels of TJP1 could potentially determine an effective treatment for patients with multiple myeloma.

Biomarker can help determine the most effective treatment for patients with multiple myeloma.

Patients taking mitoxantrone for multiple sclerosis found to have higher rates of breast and colorectal cancers and leukemia.

Patients administered mitoxantrone for multiple sclerosis carry higher rates of breast and colorectal cancers and leukemia.

Blincyto granted priority status to treat a form of acute lymphoblastic leukemia.

Animal model of malignant plasma-cell disease may accelerate new treatments for multiple myeloma.

Rapamycin may effectively treat patients with venous malformations.

The cost of oral cancer drugs spiked six-fold within the last 14 years.

Methotrexate and decadron could lower relapse rates of patients with acute lymphoblastic leukemia.

Medi-551 antibody targets the protein CD19 found on the surface of multiple myeloma stem cells.

Anti-CD38 monoclonal antibody daratumumab (Darzalex) shows promise for patients with multiple myeloma.

All-oral treatment regimen improves response rate in multiple myeloma.

Single-cell method identifies core stem cells that cause leukemia within a tumor.

The FDA has approved venetoclax (Venclexta) as a treatment for certain patients with chronic lymphocytic leukemia.

The FDA has approved venetoclax (Venclexta) as a treatment for certain patients with chronic lymphocytic leukemia.

Inhibiting GCN5 enzyme may lead to reduced remission risks and improved cure rates.

Venclexta is designed to trigger a natural process that helps cells self-destruct in chronic lymphocytic leukemia (CLL).

Venetoclax (Venclexta)is the first treatment approved by the FDA that inhibits the B-cell lymphoma 2 (BCL-2) protein.

A flood of new therapies approved last year offer new hope for patients with multiple myeloma.